보툴리눔 톡신 시장 : 제품별(A형 보툴리눔 톡신, B형 보툴리눔 톡신), 용도별(미용, 치료), 최종 사용자별(병원, 전문의와 피부과 클리닉, 기타) - 세계 기회 분석 및 산업 예측(2021-2031년)

The global Botulinum toxin market accounted for $5814.9 million in 2021, and is expected to reach $13132.72 million by 2031, registering a CAGR of 8.6% from 2022 to 2031.

Botulinum toxin, one of the most poisonous biological substances known, and is a neurotoxin produced by the bacterium Clostridium botulinum. C. Botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C1, C2, D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, causing muscle paralysis. The weakness induced by injection with botulinum toxin A usually lasts about three months.

Botulinum toxins now play a significant role in the management of a wide variety of medical conditions, especially strabismus and focal dystonia and some chronic conditions that respond only partially to medical treatment. The list of possible new indications is rapidly expanding. The aesthetic applications include correction of lines, creases and wrinkling all over the face, chin, neck, and chest to dermatological applications such as hyperhidrosis. Injections with botulinum toxin are generally well tolerated and side effects are few. A precise knowledge and understanding of the functional anatomy of the mimetic muscles is necessary to correctly use botulinum toxins in clinical practice.

The botulinum toxin market is expected to experience significant growth during the forecast period owing to surge in demand for cosmetic non-invasive surgical procedures, new product launches, increase in affordability and amendments in reimbursement policies to cover botulinum injections. In addition, rise in number of botulinum toxin procedure further facilitates the growth of the market. However, side effects associated with Botox procedures and high cost of these procedures are expected to impede the market growth in emerging region. In contrast, rise in investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin are anticipated to provide significant growth opportunities for the botulinum toxin market.

The Botulinum toxin market is segmented on the basis of product, application, end user and region. On the basis of product, the market is classified into botulinum toxin type A and botulinum toxin type B. On the basis of application, the market is divided into aesthetic and therapeutic. On the basis of end user, the market is classified into hospitals, specialty & dermatology clinics and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global botulinum toxin market. The key companies profiled in the report include Merz Pharma GmbH And Co. Kgaa, Abbvie Inc (Allergan), Ipsen Group, Revance Therapeutics Inc, Medy-Tox, Inc., Hugel, Inc., Galderma, Us Worldmed, Llc ,Evolus Inc., and Daewoong Pharmaceutical.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the botulinum toxin market analysis from 2021 to 2031 to identify the prevailing botulinum toxin market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the botulinum toxin market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global botulinum toxin market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

• Aesthetic
• Therapeutic

By Product

• Botulinum Toxin Type A
• Botulinum Toxin Type B

By End User

• Hospitals
• Specialty and Dermatology Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
• Key Market Players
  • REVANCE THERAPEUTICS INC
  • Medy-Tox, Inc.
  • GALDERMA
  • US WORLDMED, LLC
  • Abbvie Inc (Allergan)
  • DAEWOONG PHARMACEUTICAL
  • Ipsen Group
  • MERZ PHARMA GMBH AND CO. KGAA
  • HUGEL, INC.
  • EVOLUS INC.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: BOTULINUM TOXIN MARKET, BY PRODUCT

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Botulinum Toxin Type A
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market share analysis by country
• 4.3 Botulinum Toxin Type B
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market share analysis by country

CHAPTER 5: BOTULINUM TOXIN MARKET, BY APPLICATION

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Aesthetic
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market share analysis by country
• 5.3 Therapeutic
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market share analysis by country

CHAPTER 6: BOTULINUM TOXIN MARKET, BY END USER

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospitals
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market share analysis by country
• 6.3 Specialty and Dermatology Clinics
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market share analysis by country
• 6.4 Others
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market share analysis by country

CHAPTER 7: BOTULINUM TOXIN MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Product
  • 7.2.3 North America Market size and forecast, by Application
  • 7.2.4 North America Market size and forecast, by End User
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Key market trends, growth factors and opportunities
    • 7.2.5.1.2 Market size and forecast, by Product
    • 7.2.5.1.3 Market size and forecast, by Application
    • 7.2.5.1.4 Market size and forecast, by End User
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Key market trends, growth factors and opportunities
    • 7.2.5.2.2 Market size and forecast, by Product
    • 7.2.5.2.3 Market size and forecast, by Application
    • 7.2.5.2.4 Market size and forecast, by End User
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Key market trends, growth factors and opportunities
    • 7.2.5.3.2 Market size and forecast, by Product
    • 7.2.5.3.3 Market size and forecast, by Application
    • 7.2.5.3.4 Market size and forecast, by End User
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Product
  • 7.3.3 Europe Market size and forecast, by Application
  • 7.3.4 Europe Market size and forecast, by End User
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Key market trends, growth factors and opportunities
    • 7.3.5.1.2 Market size and forecast, by Product
    • 7.3.5.1.3 Market size and forecast, by Application
    • 7.3.5.1.4 Market size and forecast, by End User
    • 7.3.5.2 France
    • 7.3.5.2.1 Key market trends, growth factors and opportunities
    • 7.3.5.2.2 Market size and forecast, by Product
    • 7.3.5.2.3 Market size and forecast, by Application
    • 7.3.5.2.4 Market size and forecast, by End User
    • 7.3.5.3 UK
    • 7.3.5.3.1 Key market trends, growth factors and opportunities
    • 7.3.5.3.2 Market size and forecast, by Product
    • 7.3.5.3.3 Market size and forecast, by Application
    • 7.3.5.3.4 Market size and forecast, by End User
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Key market trends, growth factors and opportunities
    • 7.3.5.4.2 Market size and forecast, by Product
    • 7.3.5.4.3 Market size and forecast, by Application
    • 7.3.5.4.4 Market size and forecast, by End User
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Key market trends, growth factors and opportunities
    • 7.3.5.5.2 Market size and forecast, by Product
    • 7.3.5.5.3 Market size and forecast, by Application
    • 7.3.5.5.4 Market size and forecast, by End User
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Key market trends, growth factors and opportunities
    • 7.3.5.6.2 Market size and forecast, by Product
    • 7.3.5.6.3 Market size and forecast, by Application
    • 7.3.5.6.4 Market size and forecast, by End User
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Product
  • 7.4.3 Asia-Pacific Market size and forecast, by Application
  • 7.4.4 Asia-Pacific Market size and forecast, by End User
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Key market trends, growth factors and opportunities
    • 7.4.5.1.2 Market size and forecast, by Product
    • 7.4.5.1.3 Market size and forecast, by Application
    • 7.4.5.1.4 Market size and forecast, by End User
    • 7.4.5.2 China
    • 7.4.5.2.1 Key market trends, growth factors and opportunities
    • 7.4.5.2.2 Market size and forecast, by Product
    • 7.4.5.2.3 Market size and forecast, by Application
    • 7.4.5.2.4 Market size and forecast, by End User
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Key market trends, growth factors and opportunities
    • 7.4.5.3.2 Market size and forecast, by Product
    • 7.4.5.3.3 Market size and forecast, by Application
    • 7.4.5.3.4 Market size and forecast, by End User
    • 7.4.5.4 India
    • 7.4.5.4.1 Key market trends, growth factors and opportunities
    • 7.4.5.4.2 Market size and forecast, by Product
    • 7.4.5.4.3 Market size and forecast, by Application
    • 7.4.5.4.4 Market size and forecast, by End User
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Key market trends, growth factors and opportunities
    • 7.4.5.5.2 Market size and forecast, by Product
    • 7.4.5.5.3 Market size and forecast, by Application
    • 7.4.5.5.4 Market size and forecast, by End User
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Key market trends, growth factors and opportunities
    • 7.4.5.6.2 Market size and forecast, by Product
    • 7.4.5.6.3 Market size and forecast, by Application
    • 7.4.5.6.4 Market size and forecast, by End User
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Product
  • 7.5.3 LAMEA Market size and forecast, by Application
  • 7.5.4 LAMEA Market size and forecast, by End User
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Key market trends, growth factors and opportunities
    • 7.5.5.1.2 Market size and forecast, by Product
    • 7.5.5.1.3 Market size and forecast, by Application
    • 7.5.5.1.4 Market size and forecast, by End User
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Key market trends, growth factors and opportunities
    • 7.5.5.2.2 Market size and forecast, by Product
    • 7.5.5.2.3 Market size and forecast, by Application
    • 7.5.5.2.4 Market size and forecast, by End User
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Key market trends, growth factors and opportunities
    • 7.5.5.3.2 Market size and forecast, by Product
    • 7.5.5.3.3 Market size and forecast, by Application
    • 7.5.5.3.4 Market size and forecast, by End User
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Key market trends, growth factors and opportunities
    • 7.5.5.4.2 Market size and forecast, by Product
    • 7.5.5.4.3 Market size and forecast, by Application
    • 7.5.5.4.4 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 REVANCE THERAPEUTICS INC
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Medy-Tox, Inc.
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 galderma
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 US WORLDMED, LLC
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Abbvie Inc (Allergan)
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 DAEWOONG PHARMACEUTICAL
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Ipsen Group
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 MERZ PHARMA GMBH AND CO. KGAA
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 HUGEL, INC.
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 EVOLUS INC.
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments